Trajektorie změn II v přístupu k terapii diabetu 2. typu v postproduktivním věku injekčními preparáty (inkretiny a inzulin) v letech 2008-2019 - vlastní zkušenost
| Title in English | Trajectories of changes II - in the approach to the treatment of type 2 diabetes in post-productive age by injectable preparations (increatins and insulin) in the years 2008-2019 - our own experience |
|---|---|
| Authors | |
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | Geriatrie a gerontologie |
| MU Faculty or unit | |
| Citation | |
| Web | https://www.prolekare.cz/casopisy/geriatrie-gerontologie |
| Keywords | Older age; injectable treatment of type 2 diabetes; incretin mimetics; insulin; analogues; changes in the aproach to therapy in the past 12 years |
| Description | On the one hand, there is no clear consensus on the initiation of insulin therapy in type 2 diabetes (DM2T), however, even in old age, its initiation or intensification should not be excessively delayed or postponed, either by patients or physicians. During 2019, 2332 DM2T patients were treated in our diabetological outpatient clinic DIASTOP. Of these, 770 (31%) were treated with injectable preparations, i. e. GLP1 agonists, conventional or intensified insulin therapy, possibly in combination with oral antidiabetics (OAD) and the diet. In the cohort, we analyzed: age, duration of diabetes, and in particular, we focused on the changing trends in DM2T treatment over the past 12 years (i. e. 2008-2019) in the use of increatins and insulin. Duration of DM2T 15,7+- 9,1 r. Analysis of DM2T therapy over 12 years showed a significant increase in the use of insulin therapy in the period 2008-2019 (from 12,2 % to 29 %). KIT - combination of insulin with OAD was used in 17,1 %. Insulin alone was intensively used in 12 % DM2T; incretins in 2019 in 2 % of the diabetics. This intensification of DM2T therapy also led to better compensation. Our results show a significant increase in the use of conventional and intensified insulin therapy and, more recently, the use of incretins in DM2T therapy. |
| Related projects: |